Waterfall plot for all patients TBP (n=692) at the time of progressive disease showing those in blue that did not have subsequent tumor response ≥30% from baseline during their TBP, those in red that had subsequent tumor response from baseline (n=20), those in green that had subsequent tumor response from PD (n=58), and those in orange that had both (n=37). Those with no assessed target tumor burden at time of progression are blank. patients who progressed at first assessment due to target lesion progression and were continued on anti PD-1 agent with at least one subsequent assessment. Of those 176 patients, 133 had subsequent increased or unchanged target lesion tumor burden and 43 had exhibited any reduction in tumor burden, including 16 who had a decrease in tumor burden of ≥ 30% from their tumor burden at the time of RECIST-defined PD. Ten patients decreased tumor burden from the 20% PD level but not back to baseline, n=21 decreased below their baseline level and n=12 patients ultimately reduced tumor burden to ≥30% of baseline burden. Tables   Appendix Table S1 : Classification 
Reason for Progression

